1. Akabayashi, A., Wahlestedt, C., Alexander, J. T., and Leibowitz, S. F. (1994). Specific inhibition of endogenous neuropeptide Y synthesis in arcuate nucleus by antisense oligonucleotides suppresses feeding behavior and insulin secretion.Mol. Brain Res. 2155–61.
2. Bennett, C. F., Condon, T. P., Grimm, S., Chan, H., and Chain, M.-Y. (1994). Inhibition of endothelial cell adhesion molecule expression with antisense oligonucleotides.J. Immunol. 1523530–3540.
3. Breslauer, K. J., Frank, R., Blocker, H., and Marky, L. A. (1986). Predicting DNA duplex stability from the base sequence.Proc. Natl. Acad. Sci. USA 833746–3750.
4. Brysch, W., Magal, E., Louis, J. C., Kunst, M., Klinger, I., Schlingensiepen, R., and Schlingensiepen, K.-H. (1994a). Inhibition of p185/c-erbB-2 proto-oncogene expression by antisense oligodeoxynucleotides down-regulates p185-associated tyrosine-kinase activity and strongly inhibits mammary tumor-cell proliferation.Cancer Gene Ther. 199–105.
5. Brysch, W., Rifai, A., Tischmeyer, W., and Schlingensiepen, K.-H. (1994b). Rational drug design, pharmacokinetics and organ uptake of antisense phosphorothioate oligodeoxynucleotidesin vivo. InAntisense Oligonucleotide Therapy: Current Status (S. Agrawal, Ed.), Humana Press, Totowa (in press).